Lutathera ema approval date?

What is Lutathera’s EMA approval date?

Lutathera (lutetium Lu 177 vipivotide tetraxetan) received its European Medicines Agency (EMA) marketing authorization on 26 September 2017. [1]

How can I verify the EMA approval date for Lutathera?

The EMA maintains official authorization dates in its public prescribing/assessment records. You can cross-check the approval date through the EMA product information pages or reputable regulatory databases that mirror EMA filings. [1]

Does the EMA approval date differ from other regions?

Yes. EMA approval dates are specific to the European Union regulatory review. Other markets (such as the UK, US FDA, and other countries) may have different authorization dates even if the same product is approved later or earlier. [1]

What if you meant a specific indication date?

Sometimes a company’s EU “approval date” people reference can mean either the original marketing authorization or a later label expansion for additional indications. If you share which indication you mean (e.g., GEP-NETs vs. another labeled use), the relevant EU authorization date may be different from the initial 2017 approval. [1]

Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera